| Nome |
# |
|
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression, file e309ade2-cc68-3969-e053-3a05fe0a2c94
|
121
|
|
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART, file e309ade2-c8f7-3969-e053-3a05fe0a2c94
|
92
|
|
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART, file e309ade2-d399-3969-e053-3a05fe0a2c94
|
88
|
|
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV, file e309ade2-cb76-3969-e053-3a05fe0a2c94
|
81
|
|
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients, file e309ade2-c8f2-3969-e053-3a05fe0a2c94
|
79
|
|
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014, file e309ade2-d217-3969-e053-3a05fe0a2c94
|
71
|
|
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study, file e309ade2-d3a6-3969-e053-3a05fe0a2c94
|
69
|
|
HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients, file e309ade2-c530-3969-e053-3a05fe0a2c94
|
68
|
|
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort, file e309ade2-d360-3969-e053-3a05fe0a2c94
|
63
|
|
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort, file e309ade2-d046-3969-e053-3a05fe0a2c94
|
61
|
|
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients, file e309ade2-c6af-3969-e053-3a05fe0a2c94
|
58
|
|
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients, file e309ade2-c109-3969-e053-3a05fe0a2c94
|
57
|
|
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort, file e309ade2-d39b-3969-e053-3a05fe0a2c94
|
55
|
|
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing, file e309ade2-c57b-3969-e053-3a05fe0a2c94
|
54
|
|
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?, file e309ade2-c600-3969-e053-3a05fe0a2c94
|
54
|
|
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients, file e309ade2-ca74-3969-e053-3a05fe0a2c94
|
53
|
|
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort, file e309ade2-cb06-3969-e053-3a05fe0a2c94
|
53
|
|
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice, file e309ade2-d556-3969-e053-3a05fe0a2c94
|
53
|
|
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: data from the Icona cohort, file e309ade2-c5f3-3969-e053-3a05fe0a2c94
|
52
|
|
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study, file e309ade2-ca75-3969-e053-3a05fe0a2c94
|
52
|
|
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program, file e309ade2-cd1b-3969-e053-3a05fe0a2c94
|
52
|
|
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy, file e309ade2-d032-3969-e053-3a05fe0a2c94
|
52
|
|
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study, file e309ade2-d3cb-3969-e053-3a05fe0a2c94
|
52
|
|
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus, file e309ade2-d555-3969-e053-3a05fe0a2c94
|
52
|
|
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study, file e309ade2-d39a-3969-e053-3a05fe0a2c94
|
51
|
|
The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study, file e309ade2-cb04-3969-e053-3a05fe0a2c94
|
50
|
|
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort, file e309ade2-d3d4-3969-e053-3a05fe0a2c94
|
50
|
|
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?, file e309ade2-cbd4-3969-e053-3a05fe0a2c94
|
48
|
|
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy, file e309ade2-c879-3969-e053-3a05fe0a2c94
|
46
|
|
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: A multicentre cohort study Disease epidemiology - Infectious, file e309ade2-c8f4-3969-e053-3a05fe0a2c94
|
46
|
|
A prospective randomized trial on abacavir/ lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study), file e309ade2-cb05-3969-e053-3a05fe0a2c94
|
46
|
|
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy, file e309ade2-cd76-3969-e053-3a05fe0a2c94
|
45
|
|
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus, file e309ade2-c8f6-3969-e053-3a05fe0a2c94
|
43
|
|
Co-Infections in Critically Ill Patients with or without COVID-19: A Comparison of Clinical Microbial Culture Findings, file e309ade4-06ee-3969-e053-3a05fe0a2c94
|
42
|
|
HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients, file e309ade4-4d45-3969-e053-3a05fe0a2c94
|
41
|
|
The role of stage-specific oligonucleotide primers in providing effective laboratory support for the molecular diagnosis of reactivated Toxoplasma gondii encephalitis in patients with AIDS, file e309ade0-4933-3969-e053-3a05fe0a2c94
|
39
|
|
Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: The D:A:D study, file e309ade2-dde7-3969-e053-3a05fe0a2c94
|
34
|
|
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy, file e309ade4-d546-3969-e053-3a05fe0a2c94
|
34
|
|
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort, file e309ade4-6b31-3969-e053-3a05fe0a2c94
|
31
|
|
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison, file e309ade2-cc69-3969-e053-3a05fe0a2c94
|
30
|
|
null, file e309ade2-c65b-3969-e053-3a05fe0a2c94
|
15
|
|
Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated HCV-related condition in the real life practice, file e309ade2-c655-3969-e053-3a05fe0a2c94
|
14
|
|
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL, file e309ade2-cb0e-3969-e053-3a05fe0a2c94
|
14
|
|
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study, file e309ade2-dde1-3969-e053-3a05fe0a2c94
|
10
|
|
Optimization of hepatitis C virus screening strategies by birth cohort in Italy, file e309ade4-6c0a-3969-e053-3a05fe0a2c94
|
10
|
|
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort, file e309ade4-85e5-3969-e053-3a05fe0a2c94
|
10
|
|
null, file e309ade2-c823-3969-e053-3a05fe0a2c94
|
8
|
|
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV, file e309ade2-dea4-3969-e053-3a05fe0a2c94
|
8
|
|
PITER: An ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in Italy, file e309ade2-deef-3969-e053-3a05fe0a2c94
|
8
|
|
COVID-19 in eastern Emilia: an unusual epidemiology in Northern Italy, file e309ade2-bd27-3969-e053-3a05fe0a2c94
|
6
|
|
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen, file e309ade2-dddf-3969-e053-3a05fe0a2c94
|
6
|
|
Optimization of hepatitis C virus screening strategies by birth cohort in Italy, file e309ade4-a68c-3969-e053-3a05fe0a2c94
|
6
|
|
Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the Icona Foundation Cohort, file e309ade5-38a6-3969-e053-3a05fe0a2c94
|
6
|
|
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort, file e309ade4-9662-3969-e053-3a05fe0a2c94
|
5
|
|
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress?, file 73c00d70-a72c-41d2-8988-3535910bf388
|
4
|
|
Evaluation of HIV Antiretroviral Therapy, Residual Viremia, and Immune Replacement as Possible Factors that Can Affect Systemic Inflammation, file e309ade1-9fc2-3969-e053-3a05fe0a2c94
|
4
|
|
L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV, file e309ade4-ebaa-3969-e053-3a05fe0a2c94
|
4
|
|
Entheseal involvement in asymptomatic human immunodeficiency virus infected patients: preliminary results of a clinical and ultrasonographic study, file e309ade1-e607-3969-e053-3a05fe0a2c94
|
3
|
|
Detection of Parvovirus B19 and Chlamydophila pneumoniae in a Patient with Atypical Sarcoidosis, file e309ade2-a1c1-3969-e053-3a05fe0a2c94
|
3
|
|
Expression of toxoplasmic 65 kDa cystic mRNA by RT-PCR in patients with Toxoplasma gondii infection relapses, file e309ade0-2c5a-3969-e053-3a05fe0a2c94
|
2
|
|
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study, file e309ade2-c5ff-3969-e053-3a05fe0a2c94
|
2
|
|
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort *, file e309ade2-c6d3-3969-e053-3a05fe0a2c94
|
2
|
|
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen, file e309ade2-c6d8-3969-e053-3a05fe0a2c94
|
2
|
|
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison, file e309ade2-cc6a-3969-e053-3a05fe0a2c94
|
2
|
|
null, file e309ade0-27d2-3969-e053-3a05fe0a2c94
|
1
|
|
Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens, file e309ade2-c8ed-3969-e053-3a05fe0a2c94
|
1
|
|
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study, file e309ade2-d3c8-3969-e053-3a05fe0a2c94
|
1
|
|
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients, file e309ade4-e80c-3969-e053-3a05fe0a2c94
|
1
|
|
Procalcitonin Predicts Bacterial Infection, but Not Long-Term Occurrence of Adverse Events in Patients with Acute Coronary Syndrome, file e309ade5-16c1-3969-e053-3a05fe0a2c94
|
1
|
| Totale |
2377 |